Lupin Ltd
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Lupin Ltd is currently navigating a transitional phase characterized by a strategic pivot towards complex generics and biosimilars, as management anticipates normalization in US revenues due to increased competition for legacy products. The company's focus on launching over 50 new products in the US, alongside strong growth in the Indian market driven by chronic therapies, supports Vista's forecast of moderated revenue growth and margin pressures. While the outlook for the US market remains cautious, the anticipated benefits from favorable currency depreciation and a robust pipeline of innovative products provide a foundation for long-term growth. However, execution risks related to regulatory approvals and competitive dynamics in the US market warrant close monitoring. Over the next 12-24 months, key opportunities include expanding the specialty portfolio in Europe and leveraging the strong performance in India, while headwinds may arise from rising input costs and pricing pressures in the US. Overall, Lupin's strategic focus on innovation and geographic diversification positions it well for future growth, despite the challenges ahead
Why We Like This Stock
- Strong growth in the Indian market, particularly in chronic therapies, supports revenue stability
- A robust pipeline of over 50 product launches in the US, including biosimilars, positions Lupin for future growth
- Favorable currency depreciation is expected to enhance revenue for export-oriented operations
Things To Watch Out For
- Increased competition for key US products like Tolvaptan and Mirabegron is likely to pressure margins
- Rising input costs and pricing pressures in the US market may constrain profitability
- Execution risks related to regulatory approvals and product launch timelines could impact growth
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 20,011 | 22,708 | 27,958 | 30,580 | 34,071 |
| Profit Before Tax (Cr.) | 2,391 | 3,970 | 7,431 | 7,053 | 7,562 |
| PBT Margin | 11.9% | 17.5% | 26.6% | 23.1% | 22.2% |
| Net Profit (Cr.) | 1,766 | 2,990 | 5,779 | 5,490 | 5,864 |
| Earnings Per Share | 38.2 | 64.9 | 125.9 | 119.7 | 128.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| HSBC | ▲ Buy | 2,500 | 22-Sep-2026 |
| Nomura | ▲ Buy | 2,675 | 17-Sep-2026 |
| Kotak Securities | ► Add | 2,525 | 02-Sep-2026 |
| Bernstein | ▲ Outperform | 2,707 | 27-Aug-2026 |
| Citigroup | ▼ Sell | 2,050 | 27-Aug-2026 |
| Deven Choksey | ► Accumulate | 2,280 | 10-Aug-2026 |
| Prabhudas Liladhar | ► Accumulate | 2,500 | 10-Aug-2026 |
| ICICI Securities | ▼ Reduce | 2,200 | 09-Aug-2026 |
| Motilal Oswal | ► Neutral | 2,500 | 08-Aug-2026 |
| Morgan Stanley | ► Equalweight | 2,750 | 07-Aug-2026 |
| Geojit Financials | ▲ Buy | 2,606 | 04-Jun-2026 |
| CLSA | ▲ Buy | 2,690 | 11-May-2026 |
| Macguire | ▲ Buy | 2,450 | 11-May-2026 |
| BOB Capital Markets | ▲ Buy | 2,900 | 10-May-2026 |
| Elara Capital | ► Accumulate | 2,447 | 23-Apr-2026 |
Company Overview
Show Company Profile
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.